Cardiovascular Diseases Clinical Trial
To investigate the genetic influence of candidate gene polymorphisms on risk factors for the metabolic insulin resistance syndrome in Japanese American sibships and kindreds. The original grant in 1994 had as its objective to understand the genetic epidemiology of coronary heart disease (CHD) risk factors in Japanese- American families with probands living in Seattle, Washington.
BACKGROUND:
Although each of the risk factors have recently been associated with increased risk of CHD
and are known to be genetically influenced, none of them have been investigated in a large
sample of American families of Japanese ancestry. The project represents a unique and timely
opportunity to characterize the genetic epidemiology of CHD risk factors among Japanese
Americans. The findings could lead to the development of effective preventive strategies
targeted to subgroups of individuals with high risk due to underlying genetic
susceptibility.
DESIGN NARRATIVE:
In the original study, several hypotheses were tested, including: 1) that a predominance of
small LDL particles (ALP phenotype B), as determined by gradient gel electrophoresis, was
inherited as a single gene trait in Japanese-American kindreds and to compare these results
with previous studies in Caucasian families; 2) that ALP-B was associated with risk factors
characteristic of the insulin resistance syndrome and NIDDM among individual
Japanese-American family members. 3) that plasma levels of Lp(a) were inversely associated
with apo(a) size phenotypes, as determined by high- resolution SDS-agarose-gel
electrophoresis followed by immunoblotting, in individual Japanese-American subjects, and to
compare and contrast these associations with those previously reported in Caucasians and
other ethnic groups; 4) that in addition to apo(a) gene effects, the segregation of plasma
levels of Lp(a) in families was nherited consistent with the presence of another single
major gene effect. The study also established a repository of frozen white cells for future
genetic studies of candidate genes associated with risk of CHD in Japanese Americans. These
hypotheses were all tested based on blood samples, blood pressure and anthropometric
measurements, and questionnaire data from 33 Japanese-American kindreds identified through
participants in the ongoing Japanese-American Community Diabetes Study in Seattle. The
kindreds consist of 126 nuclear families and 443 individual family members, including
probands, siblings, spouses, offspring and nieces and nephews of full Japanese descent.
In 1998, the renewal has three specific aims. The first aim was to identify genetic
influences on the risk factors that characterize ther metabolic insulin resistance syndrome
(including fasting insulin, proinsulin, C-peptide and glucose; body weight and waist
circumference; lipoproteins; blood pressure; fibrinogen; factor VII and plasminogen
activator inhibitor. Statistical genetic analysis approaches used in the first aim included
univariate complex segregation analysis, factor analysis, and quantitative multivariate
genetic analysis. The second specific aim was to test for genetic linkage between specific
candidate genes involved in lipid metabolism, carbohydrate metabolism, blood pressure,
obesity, and hemostasis with genetically influenced risk factors of the metabolic syndrome
in Japanese-Americans. The third specific aim was, when the DNA repository had been
completed (750 samples by the end of year four), to apply to the NHLBI Mammalian Genotyping
Service to perform a whole genome screen to identify new genes involved in susceptibility to
the metabolic syndrome.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|